INTRODUCTION
Concanavalin A, a globulin obtained from the common jackbean plant (Canavalia ensiformis), combines readily with compounds containing sugars with unmodified hydroxyl groups at C-3, C-4, and C-6 of the D-arabinohexopyranosyl ring (1, 2) . Among the substances possessing these carbohydrate moieties are glycoproteins (3) , which may be precipitated from solutions by the addition of concanavalin A (4) (5) (6) (7) . This property has been exploited in the separation of yM globulins from human serum (7) . The concanavalin A can be displaced from the precipitated protein by the addition of methyl a-D-glucOside (7, 8) and the proteins then separated from the concanavalin A by column chromatography (7) .
Hershgold and Sprawls (9) suggested that human antihemophilic factor (AHF, factor VIII) might be a glycoprotein. The experiments we shall describe agree with this concept, since concanavalin A precipitated significant amounts of antihemophilic factor from human Dr. Ratnoff is a Career Investigator of the American Heart Association.
Received for publication 3 September 1968. plasma. Combining precipitation of antihemophilic factor by concanavalin A with other precipitation (10) (11) (12) and adsorption (13) techniques, we were able to prepare small amounts of human antihemophilic factor, containing 5-11.5 units/mg of protein, with great rapidity. Subsequent filtration through columns of agarose (9) allowed an estimation of molecular size but with such loss of activity that no additional purification was achieved.
METHODS Cryoprecipitated fractions of human plasma were prepared from blood drawn from the antecubital veins of normal adult volunteers, using polystyrene syringes coated with silicone oil 15 min at 3500 rpm. The supernatant plasma was distributed in 30-ml aliquots into silicone-coated Lusteroid tubes, and quick-frozen by immersion in a mixture of 95% ethanol and dry ice. Immediately thereafter, the frozen plasmas were thawed for 8 hr in a melting ice bath, and centrifuged at 10,000 rpm for 10 min. The supernatant plasma was discarded, and the cryoprecipitated material stored at -70'C until used. A cryoprecipitate was prepared in an identical manner from a patient with known severe classic hemophilia. dissolved in 0.15 M sodium chloride solution, or prepared by the method of Agrawal and Goldstein (14) as modified by Leon (7) and dissolved in 0.1 M sodium phosphate (pH 6.2). The concentration of protein in the two preparations varied from 10 to 18 mg/ml. Sepharose 4-B (Pharmacia Fine Chemicals Inc., New Market, N. J.), a spherical agarose gel with particle size of 30-200u in the swollen state and approximate fractionation range for molecular weights of 1 X 104 to 3 X 106 (15) , was added to sufficient barbital-saline buffer to make a thick slurry. A 33 X 0.9 cm glass column was filled with barbitalsaline buffer and the outlet tubing was raised to the level of the fluid meniscus. 33 cc of the Sepharose 4-B slurry were added intermittently to the barbital-saline buffer in the column. As the material sedimented, the outlet tubing was slowly lowered to the operating pressure of approximately 60 cm of water at the outlet. The column of Sepharose, 30 cm high by 0.9 cm in diameter, was washed in the cold with three column volumes of barbital-saline buffer. Rabbit antibody to human antihemophilic factor was prepared by injecting a mixture of equal parts of antigen, containing 40 Ag of protein, and Freund's complete adjuvant (Difco Laboratories, Detroit, Mich.) into the footpads and toepads of white New Zealand female rabbits. The antigen used was agarose column-purified human antihemophilic factor, separated by the method to be described. 1 month later, the same amount of antigen, without adjuvant, was injected intravenously into the same rabbits, and 7 days later blood was drawn by cardiac puncture and allowed to clot in glass tubes. The blood was kept at 40C overnight and then centrifuged at 3500 rpm for 10 min. Y'9 volume of 0.1 M sodium oxalate and 10 mg of calcium phosphate were added to each ml of serum, the mixture agitated for 10 min at room temperature, and the treated serum then separated by centrifugation at 3500 rpm for 15 min, and heated at 560C for 30 min. The serum contained an antibody directed against antihemophilic factor, as estimated by its effect upon the clot-promoting function of this substances, using a method described for the study of anti-Hageman factor antibody (17) . The (22, 23) using rabbit antihuman fibrinogen.
To prepare partially purified antihemophilic factor (Table  I) , the cryoprecipitate separated from 180 ml of plasma was dissolved in 8 ml of barbital-saline buffer and divided into two parts, each of which was treated separately. In this step antihemophilic factor was usually purified 25-to 30 -fold with respect to protein.
In duplicate, one part of the reconstituted cryoprecipitate, about 5 ml in volume, was mixed by careful swirling with 1.34 g of fl-alanine (Calbiochem, Los Angeles, Calif.). This amount was sufficient to make the concentration of this amino acid 3 molal; fi-alanine precipitates antihemophilic factor (12) . The mixture was allowed to stand in a melting ice bath for 30 min and then centrifuged for 5 min at 10,000 rpm. The supernatant solution was discarded. The precipitate was dissolved by tapping with a silicone-coated rod, using sufficient barbital-saline buffer to bring the volume to 5 ml. This solution was rapidly poured into an equal volume of concanavalin A solution. The mixture was stored in an ice bath for 15 min, and the white granular precipitate which formed was separated by centrifugation at 10,000 rpm for 5 min. The supernatant solution was discarded and the precipitate washed once with 10 ml of cold barbital-saline buffer, recentrifuged, and dissolved by the addition of sufficient 1.0 M methyl a-D-glucoside (Sigma Chemical Co.) to bring the total volume to 5 ml. Solution was aided by warming the mixture at 370C for 5-10 min, and tapping the precipitate with a silicone-coated glass stirring rod.
The dissolved concanavalin A-precipitated material was next added to 1.34 g of 8-alanine, to form a solution 3 molal with respect to the amino acid, and rechilled in an ice bath for 15 min. The precipitate which formed was separated by centrifugation at 10,000 rpm, washed once with 10 ml of a solution of 1.0 M methyl ca-D-glucoside in 3.0 molal p-alanine to remove any remaining traces of concanavalin A, recentrifuged, and dissolved in barbital-saline buffer to a final volume 1/10-1/20 that of the original plasma.
In this state the partially purified antihemophilic factor still contained fibrinogen. This was removed by adsorption onto bentonite as suggested by Soulier (13 Partially purified antihemophilic factor fraction. mg/ml of solution. The bentonite tended to adhere to the sides of the silicone-coated tube if added to the solution, whereas a compact lump of bentonite could be carefully put in the tube before addition of the fraction, thus allowing maximal contact of the fraction with the bentonite. The mixture was agitated by hand at room temperature for exactly 10 min and centrifuged for 5 min at 10,000 rpm. Concanavalin A-Precipitated Antihemophilic Factoragar-gel imnmunodiffusion technique using rabbit antihuman antihemophilic factor antiserum in the center well. Fractions rich in antihemophilic factor before gel filtration, but after bentonite treatment and concentration were subjected to ultracentrifugation by applying 0.3 ml samples to the surface of 5-20% sucrose gradients in aluminum layering cups (Beckman Instruments, Inc., Fullerton, California) (27) . Subribosomal particles (40S and 58S) and porcine thyroglobulin (19S) were applied to separate gradients. The samples were centrifuged at 35,000 rpm, 0C. for 3 hr. Fractions were collected, in the cold, by puncturing the bottom of the centrifuge tube. The samples were then diluted with four parts of 5%o sucrose in Tris buffer (0.15 M pH 7.4). These fractions were assayed immediately for antihemophilic activity and their protein content measured.
All centrifugations were at 20C. Those at 3500 rpm were performed in an International PR-2 centrifuge and those at 10,000 rpm in the angle head of a Sorvall RC-2 centrifuge (Ivan Sorvall, Inc., Norwalk, Conn.). Ultracentrifugation was performed at 35,000 rpm (100,000 g average) in a Beckman L-2 ultracentrifuge using a SW-50L swinging bucket head. Protein was estimated by the method of Lowry, Rosebrough, Farr, and Randall (28) or by transmittance at 260 m/z and 280 mju in a Beckman model DU spectrophotometer using an absorbance meter (Gilford Instrument Company, Oberlin, Ohio).
RESULTS
Studies of antihemophilic factor prepared by concanavalin A precipitation with gel filtration. Before gel filtration, concentrates of antihemophilic factor prepared from cryoprecipitates by the technique described contained 5.0-11.5 units of 'activity/mg of protein. In contrast, normal plasma. which contains about 70 mg of protein, contains one unit of antihemophilic factor, or a specific activity of about 0.014 units/mg. Thus, the purification achieved was approximately 350-to 800-fold compared to the plasma from which the fractions were separated. The preparations frequently contained small amounts of proaccelerin, never more than one-half of 1% that of the original plasma, and traces of Hageman factor, PTA, and plasminogen; no fibrinogen was detectable either immunologically or by the addition of thrombin. Free concanavalin A could not be detected immunologically in the purified fractions.
The presence of antihemophilic factor in the purified fractions was detected by their capacity to correct the defect in the plasma of patients known to have classic hemophilia. That this corrective effect was attributable to antihemophilic factor was confirmed by its ready destruction by a circulating anticoagulant directed against this substance (Table II) . Samples of the fraction or normal plasma, incubated with barbital-saline buffer, showed no significant loss of antihemophilic activity after incubation for 3 hr at 370C. In contrast, incubation of the fraction with the plasma of a patient with a circulating anticoagulant resulted in inactivation of antihemophilic factor. Similarly, the anticoagulant inactivated more than 99% of the antihemophilic activity of normal plasma during the same time interval.
The identity of the procoagulant in purified fractions with antihemophilic factor was further confirmed in studies of the effect of specific antisera. These antisera were invariably of low titer, whether because the antihemophilic factor was poorly antigenic or because only a small portion of the protein in the fractions used for immunization was antihemophilic factor (Table III) Conceivably, the precipitation of antihemophilic factor by concanavalin A was fortuitous, the clotting factor being coprecipitated with a glycoprotein. To test this, bentonite-adsorbed fractions were mixed with an equal mixture of concanavalin A. The minute precipitate which formed contained antihemophilic factor, while none was detected in the supernatant solution (Table IV) . Perhaps soluble complexes of concanavalin A and antihemophilic factor were present in the supernatant solution but not detected since no methyl a-D-glucoside was present. The supernatant solution was diluted 20-fold in barbital-saline buffer before assay to diminish the anticoagulant effect of concanavalin A. Notably, more than 90% of antihemophilic activity was lost during the reprecipitation process.
As others have found, stabilizing antihemophilic factor in dilute protein solution proved a formidable problem in these experiments. Lyophilization resulted in a loss of 50% of the antihemophilic factor activity found in the prelyophilized sample. In addition, within 30 min after reconstitution of the lyophilized sample, there was total disappearance of measurable antihemophilic activity. Adding 0.002 M magnesium chloride, manganous chloride, calcium chloride, or cysteine or 5% fructose to the fraction did not stabilize its antihemophilic activity. Making the fraction 50% with respect to glycerol resulted in recovery of up to 90% of the original antihemophilic activity after 5 days storage at -20'C. After dilution of the glycerol-treated fraction 20-fold in barbital-saline buffer, however, rapid decay of antihemophilic activity ensued.
After sucrose gradient ultracentrifugation of concanavalin-precipitated preparations, antihemophilic ac- Studies of antihemophilic factor prepared by concanavalin A precipitation and agarose gel filtration. Filtration of antihemophilic factor prepared by concanavalin A precipitation through columns of agarose separated the fraction into at least two components (Fig. 2) . Approximately 45 min after application of the sample, antihemophilic activity appeared in association with the first protein peak, usually a few ml beyond the void volume; none was detectable in the second peak. Using this rapid filtration step, we were unable to increase the purification of antihemophilic factor, presumably because this agent deteriorated during the procedure; indeed, in some preparations, activity appeared to decrease. Gelfiltered antihemophilic factor contained no measurable amounts of any known clotting factor or plasminogen.
Proof that gel filtration separated antihemophilic factor from contaminating proteins was obtained by disc electrophoresis. Cryoprecipitated antihemophilic factor contained [14] [15] [16] stainable bands when subjected to electrophoresis on acrylamide gel (Fig. 3) . In contrast, the electrophoretic pattern of a fraction 800-fold purified, but not filtered through agarose, contained only 3 or 4 stainable bands, all of which were in the slow-moving gamma region. Disc electrophoresis of antihemophilic factor fractions after gel filtration did not result in visible bands when stained with Coomassie Blue. Because of the suggestion that antihemophilic factor might be a glycoprotein (9), we stained these gels with PAS. preparations may have been too large to enter even the largest pore gel (3 3/4%). In addition, incorporating antihemophilic factor in polymerizing acrylamide gel, as in the case of the sample gel, might have impeded the movement of this factor during electrophoresis. Attempts to demonstrate the purity of antihemophilic factor by immunologic means were unsuccessful. After immunodiffusion in agar gels, four precipitin lines appeared between antibody against concanavalin A-precipitated antihemophilic factor and normal plasma, normal serum, or cryoprecipitates prepared from normal or hemophilic plasma. But no visible precipitin lines were detected between the antisertim and concanavalin A-precipitated antihemophilic factor, either before or after gel filtration.
DISCUSSION
These experiments describe a method for purifying antihemophilic factor from human plasma as much as 800-fold. The preparations obtained were not yet pure. The method used took advantage of the precipitation of antihemophilic factor by concanavalin A. Material precipitated by concanavalin A, freed of this agent, and adsorbed with bentonite to remove fibrinogen, still contained small amounts of proaccelerin and traces of PTA, Hageman factor, and plasminogen. The preparation could be freed of detectable quantities of these contaminants by filtration through a column of agarose, but no increase in specific activity occurred, perhaps because of concomitant deterioration of the antihemophilic factor.
Our experiments provide evidence that concanavalin A precipitates antihemophilic factor. Since this plant protein reacts with carbohydrates of a particular structure (1, 2), its reaction with antihemophilic factor suggests that the latter is a glycoprotein, a view previously expressed by Hershgold (9) . The recent observation that concanavalin A interacts with certain negatively charged polyelectrolytes such as RNA and heparin does not, in all probability, bear upon the reaction between this protein and antihemophilic factor (29) . At the pH at which our experiments were performed, the charge on the molecules of antihemophilic factor was probably not great enough to induce nonspecific precipitation.
The data obtained provide a clue to the molecular size of antihemophilic factor, at least as it exists in cryoprecipitates. Using the method of Andrews (30), we estimate from gel filtration studies that the molecular weight of antihemophilic factor in our preparations was at least 2.0 million. This approximation assumes that the molecules of antihemophilic factor are spherical and that they are not complexed to some other component of plasma. This result seems compatible with data obtained by sucrose gradient ultracentrifugation of concanavalinprecipitated antihemophilic factor, in which this sub-
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L. Kass, 0. D. Ratnoff, and M. A. Leon stance was found in fractions sedimenting at approximately 40S and therefore consistent with a molecular weight above 2.0 million ' (27) . Additional estimates of molecular weight could not be made because the concentration of protein needed for such an analysis was greater than we could obtain. In earlier studies, Lewis (31) estimated by Sephadex G-200 filtration that human antihemophilic factor had a molecular weight greater than 200,000, while Hershgold and Sprawls (32) found that the sedimentation coefficient of his purified preparations was 19. In contrast, Aronson, Preiss, and Mosesson (33) gauged the molecular weight of antihemophilic factor to be 180,000, using an indirect method. Since our preparations of antihemophilic factor were prepared at 20-40C, from cryoprecipitated plasma, the possibility exists that the apparently high molecular weight of antihemophilic factor was the artefactual result of aggregation of smaller units. Alternatively, aggregates containing several active sites may exist in vivo, accounting for the data of Aronson et al. (33) . In a subsequent paper, data will be presented suggesting that in freshly drawn plasma antihemophilic factor may indeed have a molecular weight in excess of 2 million. If this is the case, antihemophilic factor is surely one of the largest proteins in human plasma.
